Food Fermentation Patents: Top Companies & Filing Trends 2026
- 58.1% concentration. The top 5 of 86 ranked assignees account for 147 of the 253 records in scope — a field where a handful of culture and ingredient specialists hold most of the claim space.
- Filing grew 17% from 2021 to 2024. From 12 records in 2021 to 14 in 2024, with 2022 the peak year so far at 36 — the clearest complete-year signal in the dataset.
- C12N and A23L dominate, C12Q stays thin. 56.5% of records touch microorganism/genetic-engineering claims and 51.4% touch food/beverage claims, while enzyme- and DNA-testing claims (C12Q) sit at just 11.9%.
Filing growth compares 2021 (12 records) with 2024 (14) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 253 records in scope (CR5), not by the ranked leaders only.
What the food fermentation patent landscape covers
This landscape draws on 253 published records spanning 2015 through the 2026 cut-off, filtered to documents that combine food fermentation language with claims on ingredient mixtures, microbial culture, processing temperature, product stability, culture conditions or gene constructs. The scope captures both classical starter-culture work and the genetic-engineering side of microbial strain design, which is why C12N claims outweigh food-processing claims under A23L in raw record count.
Filing activity is uneven year to year but has not reversed: the most recent two years in any dataset are always undercounted because publication trails filing by roughly 18 months, so 2025 and 2026 figures here should be read as still filling in rather than as a slowdown.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 253-record dataset: the year-by-year filing curve, and the IPC subclasses that carry the claim weight.
Filing trend, 2017–2026
Filings rose from 6 in 2017 to a peak of 36 in 2022, then held at 14 in 2024 — a 17% rise over the 2021-to-2024 span using the two complete years the dataset supports. Treat 2025 and 2026 as understated pending publication lag rather than as evidence of decline.
IPC subclass distribution
C12N (microorganisms & genetic engineering) and A23L (foods & non-alcoholic beverages) each cover more than half of the 253 records, followed by A61K (28.1%) and A23C dairy (23.3%). Because records can carry multiple IPC codes, these shares sum to well over 100% of the record total and should not be added together.
Shares are the percentage of the 253 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Food Fermentation Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about food fermentation patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited filings
Microencapsulation of microbial culture using octenyl succinic anhydride starch-chitosan complex coacervate (US20230323332A1)
The present invention relates to microencapsulated microbial cultures with high storage stability and methods for producing these. In particular, the present invention relates to microbial cultures formulated in complex coacervates comprising octenyl succinic anhydride (OSA) starch and chitosan, products comprising such formulations.Filed by Chr. Hansen A/S, published 2023-10-12 — illustrates the shift toward stability-engineering claims layered on top of core culture composition.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5955269A | Methods of screening foods for nutraceuticals | 95 |
| 2 | US20070009988A1 | Novel fungal proteins and nucleic acids encoding same | 73 |
| 3 | US7468267B2 | Fungal proteins and nucleic acids encoding same | 59 |
| 4 | WO1996011586A1 | Preparation of frozen fermented foods using antifreeze polypeptide-expressing microorganisms | 58 |
| 5 | US20040171065A1 | Method for expression of proteins on spore surface | 34 |
| 6 | WO2002046388A1 | Method for expression of proteins on spore surface | 28 |
| 7 | US5676985A | Antifreeze polypeptide-expressing microorganisms useful in fermentation and freezing of foods | 27 |
| 8 | WO2005019251A2 | Novel fungal proteins and nucleic acids encoding same | 23 |
| 9 | WO2009065415A1 | Polypeptides comprising an ice-binding activity | 19 |
| 10 | WO2020079026A1 | A method of manufacturing a consortium of bacterial strains | 17 |
Citation counts reward older filings simply by virtue of time in the corpus — read them as a signal of influence on later filers, not as a ranking of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three findings that shape where a new filing is likely to clear prior art and where it is likely to collide with it.
The top of the field is dense
Five assignees out of 86 ranked account for 147 of 253 records. New entrants filing on core culture-composition or strain-engineering claims are filing into territory already occupied by the leader, whose 60 records alone represent close to a quarter of the dataset.
Activity is rising, not stalling
The rise from 12 filings in 2021 to 14 in 2024, against a 2022 peak of 36, shows a field still investing rather than winding down. Later years in the dataset understate true filing volume because of publication lag, so this three-year span is the most reliable growth read available.
Testing and measurement claims are thin
While genetic engineering (C12N, 56.5%) and food formulation (A23L, 51.4%) claims are heavily filed, claims on enzyme- or DNA-based measurement and quality control (C12Q) cover just 11.9% of records — the smallest of the eight subclasses tracked here.
Older nutraceutical-screening claims still anchor the field
The most-cited record in scope, on screening foods for nutraceuticals, predates most of the filing activity in this dataset. Its citation count reflects decades of accumulated reference, not current filing pressure, and should not be read as a live competitive threat.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to food fermentation patent landscape, with the prior art for and against each one.
Who holds the claim space, and where the gate stands open
Filing is concentrated among a small set of culture and ingredient specialists, with recent-year momentum flattening even among the leaders — a signal the window for new claims may be opening rather than closing.
One assignee holds close to a quarter of the field
The top-ranked assignee's 60 records sit well ahead of fifth place at 16 and tenth place at 8, a gap that marks this as a leader-and-long-tail field rather than a fragmented one.
Recent-year filing has gone quiet at the top
Several of the most active historical assignees show zero filings in the latest tracked year, some down 100% year-on-year. That does not necessarily mean retreat — it is as consistent with publication lag as with a genuine pause — but it means the leaderboard is not currently being defended by fresh filings.
Collaboration is concentrated in a few pairings
Only 10 co-assignee pairs appear across the dataset, and the strongest single pairing accounts for 15 shared records — most filings in this field are solo efforts rather than joint ventures.
| Assignee | Recent year | YoY |
|---|---|---|
| Chr. Hansen A/S | 0 | -100% |
| Roskilde University | 0 | — |
| International N&H Denmark ApS | 0 | -100% |
| Amyra Biotech AG | 0 | — |
| IOGENETICS LLC | 0 | — |
| Danisco US Inc. | 0 | -100% |
| Unilever N.V. | 0 | — |
| PHARMABIOME AG | 0 | — |
Where to take this next
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, sourcing partners, or spotting where to file.
Check freedom-to-operate against the top 5
With 58.1% of records held by five assignees, a novelty or clearance search on any core culture-composition or strain-engineering concept should start there before broader searching.
Run a clearance search in EurekaTrack the quiet leaders for renewed activity
Several top assignees show zero filings in the latest year. Watching for a resumption is a low-cost way to catch a shift in competitive posture early.
Set up assignee monitoring in EurekaExplore the under-claimed branches
C12Q testing claims and stability-engineering approaches like OSA-starch/chitosan encapsulation sit well below the density of core formulation claims — a starting point for scoping a first claim.
Explore white space in EurekaFrequently asked questions
The dataset ranks 86 assignees, and the top 5 together account for 147 of the 253 records in scope, or 58.1%. The leading assignee alone holds 60 records, well ahead of the fifth-ranked company at 16, which makes this a leader-and-long-tail field rather than a fragmented one. Most of the concentration sits in microbial culture composition and stability-engineering claims rather than downstream food processing steps.
Filings rose from 12 in 2021 to 14 in 2024, a 17% increase over that span, with 2022 standing as the peak year so far at 36 filings. Figures for 2025 and 2026 look lower, but that reflects the roughly 18-month lag between filing and publication rather than an actual drop in activity. The most defensible read is that filing has grown rather than slowed.
Microorganism and genetic-engineering claims under IPC class C12N appear in 56.5% of the 253 records, and food and non-alcoholic beverage claims under A23L appear in 51.4%. Medicinal preparation claims (A61K) and dairy-specific claims (A23C) follow at 28.1% and 23.3% respectively. Because a single record can carry several IPC codes, these percentages overlap rather than sum to 100%.
Enzyme- and DNA-based testing and measurement claims, classified under C12Q, cover only 11.9% of the 253 records — the lowest share among the eight subclasses tracked in this dataset. Related stability-engineering approaches such as coacervate-based microencapsulation and cold-chain-resilient culture formulations also appear less densely than core composition claims. These are reasonable starting points for scoping a narrower, more defensible first claim.
US20230323332A1, assigned to Chr. Hansen A/S and published in October 2023, claims microencapsulation of microbial cultures using a complex coacervate of octenyl succinic anhydride (OSA) starch and chitosan, aimed at improving storage stability. It sits within the broader C12N and A23C claim space but is narrower than core culture-composition patents, since it addresses a specific encapsulation chemistry rather than the microorganism or fermentation process itself. Anyone designing a competing stability solution would need to review this filing's specific material combination rather than assume broad culture-composition patents already cover it.
Research Food Fermentation Patent Landscape in depth with Eureka
Go past this page: query the whole food fermentation patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.